Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies

The Elec Inc. South Korea

Overview

The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly’s Retatrutide, a triple agonist for GLP-1, GIP, and glucagon, achieved an average 28.7% weight loss in Phase 3 trials. Novo Nordisk’s CagriSema, combining GLP-1 and an amylin analogue, showed 20.4% weight reduction and is filed with the FDA. Amgen’s MariTide, a dual agonist activating GLP-1 and inhibiting GIP receptors, aims for monthly administration and has entered Phase 3.

In Depth

Background

Obesity is a global public health challenge, increasing the risk of numerous chronic diseases such as type 2 diabetes, cardiovascular disease, and certain cancers. GLP-1 (glucagon-like peptide-1) receptor agonists have revolutionized this field by demonstrating significant weight loss efficacy. However, pharmaceutical companies are now focused on developing next-generation obesity drugs that surpass GLP-1 monotherapy, aiming for even greater efficacy, reduced dosing frequency, and improved side effect profiles. Multi-agonist drugs that act on several metabolic pathways are particularly gaining attention.

Key Findings / Results

The drug development race for obesity treatments has entered a new phase, moving beyond single GLP-1 injectables to innovative drugs that target multiple hormone receptors simultaneously.

• Eli Lilly’s Retatrutide: This triple-action therapy is designed to co-activate three receptors: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. In Phase 3 clinical trials, it achieved an astonishing average weight loss of 28.7% over 68 weeks. This effect surpasses that of any existing obesity medication, indicating its potential for significant disease modification.
• Novo Nordisk’s CagriSema: This is a co-formulation of a GLP-1 receptor agonist and an amylin analogue. In Phase 3 trials, it demonstrated an average weight loss of 20.4% and has already submitted a New Drug Application to the U.S. FDA. Amylin complements GLP-1’s effects by promoting satiety and suppressing glucagon secretion.
• Amgen’s MariTide: This dual agonist features a unique mechanism of action, activating the GLP-1 receptor while inhibiting the GIP receptor. The drug aims for once-monthly administration, which could significantly enhance patient convenience. It has now entered Phase 3 clinical trials, with its efficacy and safety profile drawing considerable attention.

Technical Significance & Outlook

The emergence of these next-generation obesity drugs holds the potential to fundamentally transform the landscape of obesity treatment. Medications with multi-agonist mechanisms are expected to deliver superior weight loss effects compared to single-agonist drugs and may be applicable to a broader patient population. Reduced dosing frequency (e.g., once a month) will significantly improve patient adherence and enhance long-term treatment success rates. These drugs are anticipated to further reduce the risk of obesity-related comorbidities (such as cardiovascular disease and diabetes), offering substantial public health benefits. Intense competition among pharmaceutical companies will drive further innovation, leading to even more effective, safer, and convenient obesity treatments in the market. This signifies the establishment of a new therapeutic paradigm for metabolic diseases, extending beyond mere weight management to comprehensive metabolic health improvement. The success of such multi-agonists represents a major pharmacological triumph, demonstrating how precise modulation of multiple endocrine pathways can achieve synergistic and superior clinical outcomes compared to single-target interventions, pushing the boundaries of metabolic medicine globally.